larotaxel

Larotaxel is a third-generation, semi-synthetic taxane derivative developed for its antineoplastic (anticancer) activity. It acts by binding to tubulin, promoting microtubule assembly and stabilization while preventing their depolymerization, which inhibits cell proliferation and induces apoptosis in cancer cells. Larotaxel was designed to overcome some limitations of earlier taxanes such as paclitaxel and docetaxel, including resistance mediated by P-glycoprotein efflux pumps and poor central nervous system penetration. It has demonstrated a broad spectrum of antitumor activity in preclinical models and reached phase III clinical trials for several cancers (notably breast cancer, pancreatic cancer, bladder cancer, non-small cell lung cancer), but its development was ultimately discontinued[2][3][5][7].

Other names

larotaxel [INN]larotaxelum